Blog

Teva shares slide on generic Copaxone fears

By Steven Scheer and Tova Cohen TEL AVIV (Reuters) – Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan. Teva’s Tel Aviv shares fell to 249.80 shekels ($64) late on Sunday, the first day of trading since both news hit the market on Thursday after Israel’s

Merck's Keytruda shrinks lung cancer tumors, FDA approval sought

Merck & Co Inc’s Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body’s own disease-fighting cells. The company said it has filed for U.S. Food and Drug Administration approval of the drug as a treatment for patients with non-small cell lung cancer (NSCLC) whose disease

Merck files for FDA approval of Keytruda in lung cancer

Merck & Co Inc said on Sunday it has submitted an application to the U.S. Food and Drug Administration for its drug Keytruda as a treatment for advanced non-small cell lung cancer, the most common form of the disease. Keytruda, also known as pembrolizumab, is currently approved by the FDA for patients with advanced melanoma who are no longer responding to other therapies. The drug is part of a new

Australia to boost child vaccination with $20 mn package

Australia on Sunday unveiled a Aus$26 million (US$20 million) package to increase child vaccination rates, as it removed a religious exemption allowing parents unwilling to immunise their children to claim some government benefits. Health Minister Sussan Ley said the new measures, which will be part of the May 12 federal budget, included the establishment of a national school vaccination register and financial incentives for doctors to pursue children two months